PeterJosephDeMariaMD

Clinical Investigator, Phase 1 Clinical Trials at NEXT Oncology

Overview of Dr. DeMaria

Peter J. DeMaria, MD is a medical oncologist with a focus on early phase drug development at NEXT Oncology.

Dr. DeMaria is a graduate of the NCI-FDA Interagency Oncology Task Force, a joint fellowship program with the National Cancer Institute (NCI), National Institutes of Health (NIH), and the U.S. Food and Drug Administration (FDA). Dr. DeMaria completed an NCI-sponsored combined clinical fellowship in hematology and oncology through the NIH Intramural Research Program. He later served as a medical officer with the Office of Oncologic Diseases, Office of New Drugs, Center for Drug Evaluation and Research, FDA.

Prior to joining the federal government, he completed residency training in internal medicine and a clinical fellowship in hospice and palliative medicine at Jackson Memorial Hospital. He received his medical degree from the University of Miami Miller School of Medicine and his undergraduate degree in economics from Dartmouth College. With a focus on the development of novel cancer therapies, Dr. DeMaria’s skillset includes clinical trial methodology and analysis, clinical aspects of medical product development, and regulation to facilitate the movement of drugs, biologics, and devices from the basic bench science to commercialization.

Dr. DeMaria is certified by the American Board of Internal Medicine in medical oncology, internal medicine, and hospice and palliative medicine. He is board eligible in hematology. Active licensure in Texas and Florida.

Office
7500 Fannin St
Ste 500
Houston, TX 77054
Book by Phone+1(786) 686-8974

Education & Training

Food and Drug AdministrationFellowship, NCI-FDA Interagency Oncology Task Force Fellowship, 2019 - 2020
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2017 - 2020
University of Miami/Jackson Health SystemFellowship, Hospice and Palliative Medicine, 2016 - 2017
University of Miami/Jackson Health SystemResidency, Internal Medicine, 2013 - 2016
University of Miami Leonard M. Miller School of MedicineClass of 2013, MD
Dartmouth CollegeB.A., Economics, Cum Laude, 2002 - 2006

Certifications & Licensure

TX State Medical License 2024 - 2026
FL State Medical License 2016 - 2025
DC State Medical License 2018 - 2020
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hospice and Palliative Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Conquer Cancer Merit Award ($1000) American Society of Clinical Oncology (ASCO), 2020
NIH Outstanding Academic Achievement Award National Institutes of Health, 2020
NCI Quality Improvement Group Award ($500) National Cancer Institute, 2019
Merit Scholarship - $20,000 ($5,000/year x 4 years) University of Miami Miller School of Medicine, 2009-2013
National Merit Scholar ($2,500) National Merit Scholarship Corporation, 2002
Join now to see all

Clinical Trials

QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma Start of enrollment: 2015 May 01
Completed
Phase 2
A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer Start of enrollment: 2020 Jan 08
Completed
Phase 1

Publications & Presentations

PubMed

10 citations
Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study.
Michael J Nathenson, Junxiao Hu, Ravin Ratan, Neeta Somaiah, Robert Hsu
Clinical Cancer Research. 2022-09-15
39 citations
Cancer Vaccines.
Peter J DeMaria, Marijo Bilusic
Hematology/oncology Clinics of North America. 2019-04-01
32 citations
Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced,...
Peter Joseph DeMaria, Marijo Bilusic, Deric M. Park, Christopher R. Heery, Renee N. Donahue
The Oncologist. 2021-05-01

Journal Articles

Perspectives on drug development for the treatment of chronic myeloid leukemia in pregnant patients and patients who are breastfeeding
Cortes JE, Abruzzese E, Cardonick EH, Hernandez-Diaz S, Gutierrez J, Sardegna MS, Torres-Chavez E, Dinatale M, Lerro CC, Gehrke BJ, Shord SS, de Claro RA, Theoret MR, ..., Clinical Cancer Research, 7/5/2024
Career options for graduating oncology fellows at the NIH and FDA
DeMaria, PJ, Gao, JJ, OncLive, 6/15/2020
Giant Malignant Melanomas and their Clinical Implications: Review of Literature and Case Report.
Gishen K, DeMaria P, Khanlari M, ChoVega HJ, Feun L, Thaller S, Moller MG, Clinics in surgery, 9/1/2016
Metabolic syndrome and prevalence in an urban, medically underserved, community-based population.
Ryan, J.G., Brewster, C., DeMaria, P., Fedders, M., and Jennings, T., Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 7/2010
Join now to see all

Abstracts/Posters

A phase 1 open label trial of intravenous administration of MVA-BN-Brachyury vaccine in patients with advanced cancer.
DeMaria PJ, Lee-Wisdom K, Madan RA, Karzai FH, Donahue RN, Palena C, Jochems C, Floudas CS, Strauss J, Marté JL, Redman JM, Abdul Sater H, Korchin B, Adams T, Silberna..., American Society of Clinical Oncology (ASCO) Annual Meeting, Virtual, 6/4/2021
Association of CTNNB1 mutation subtypes with response to systemic therapy in patients with desmoid tumors: a multi-institutional retrospective study
Nathenson, M, Somaiah, N, Hsu, R, DeMaria, P, Catoe, H, Malik, K, Harris, C, Subhawong, TK, Amini, B, Jagannathan, JP, Braschi-Amirfarzan, M, Sweet, K, Feister, K, Hu,..., Connective Tissue Oncology Society Annual Meeting, Virtual, 11/21/2020
A randomized, double-blind, phase II clinical trial of GI-6301 (yeast-brachyury vaccine) versus placebo in combination with standard of care definitive radiotherapy in...
DeMaria, PJ, Bilusic, M, Park, D, Heery, CR, Madan, RA, Strauss, J, Donahue, R, Marte, J, Gilbert, M, Steinberg, SM, Schlom, J, and Gulley, JL, ASCO Annual Conference, Virtual, 5/25/2020

Lectures

Results with volumetric analysis from a phase 2 clinical trial of a yeast-brachury vaccine (GI-6301) with definitive radiation therapy in locally advanced, unresectabl...
Plenary session oral presentation at: International Chordoma Research Workshop (Virtual) - 7/16/2020
Targeted Therapies for Acute Leukemia: Safety During Pregnancy/Lactation and Labeling Consistency
White Oak, MD - 4/20/2020
Hospice and Palliative Care in the United States
Croatian Society for Palliative Medicine of the Croatian Medical Association - Vukovar, Croatia - 10/18/2019
Successful Management of Cancer Pain
Croatian Society for Palliative Medicine of the Croatian Medical Association - Vukovar, Croatia - 10/18/2019
Join now to see all

Grant Support

Rockefeller Grant ($5,000)Nelson A. Rockefeller Center for Public Policy and the Social Sciences2005

Research History

Lead Associate Investigator, Center for Cancer Research, National Cancer Institute, National Institutes of HealthNCI Protocol 20-C-0001: Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients with Advanced Cancer (NCT04134312)2020 - 2021
Associate Investigator, Center for Cancer Research, National Cancer Institute, National Institutes of HealthNCI Protocol 15-C-0118: A Randomized, Double-Blind, Phase 2 Trial of GI-6301 (Yeast-Brachyury Vaccine) Versus Placebo in Combination with Standard of Care Definitive Radiotherapy in Locally Advanced, Unresectable, Chordoma (NCT02383498)2019 - 2020
Researcher, Sylvester Comprehensive Cancer CenterCorrelation of CTNNB1 Mutation Status with Chemotherapy Response by MRI in Patients with Desmoid Tumors2015 - 2017
Research Assistant, Department of Family Medicine, University of Miami Miller School of Medicine2008 - 2009